Sacubitril

Sacubitril (AHU-377) is a potent and orally active NEP (neprilysin) inhibitor with an IC50 of 5 nM. Sacubitril is a component of the heart failure medicine LCZ696. Sacubitril can be used for the research of heart failure, hypertension and COVID-19[1][2][3].

Product Specifications

CAS Number

[149709-62-6]

Product Name Alternative

AHU-377

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Neprilysin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/AHU-377.html

Purity

99.92

Solubility

DMSO : 75 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

O=C(CCC(O)=O)N[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C[C@@H](C)C(OCC)=O

Molecular Formula

C24H29NO5

Molecular Weight

411.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Ksander GM, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12;38 (10) :1689-700.|[2]Voors AA, et al. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22 (8) :1041-7.|[3]von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8 (1) :71-8.|[4]Hegde, L.G., et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacol 11, P33 (2011) .